The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy

El-Bassiouny, Noha A.; Helmy, Maged W.; Hassan, Mohamed; Khedr, Gehan

doi:10.1016/j.clbc.2022.01.008

Cited by 19 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin D can assist in the suppression of RH+ tumors, as well as mitigate cardiometabolic effects by reducing IL-6, LHD, and cTnT, improving total antioxidant capacity (TAC), and preventing tumor growth through 27HC (27-Hydroxycholestero) and CYP27A1 [20][21][22].…”

Section: Discussionmentioning

confidence: 99%

Effects of omega-3 and vitamin D supplementation in patients with breast cancer: a systematic review

Oliveira da Silva,

Da Silva,

Weiny Barbalho Silva

et al. 2024

FNDS

View full text Add to dashboard Cite

Breast cancer (BC) is the leading cause of death among women with cancer worldwide. Nevertheless, key challenges must be addressed, as new therapies can be employed to support the main treatment and enable a better quality of life, survival and prognosis. In this paper, we described the role of omega-3 and vitamin D supplementation in patients during the main treatment. This is a systematic review of the literature from randomized clinical trials, following the PRISMA and PICOS guidelines for elaborating the guiding question and constructing the results. Our findings in this review reveal and support that omega-3 and vitamin D supplementation can help women with metastatic disease who are not receiving hormone therapy during BC treatment for HR+ (hormone receptor positive). They improve immunity and antioxidant capacity and decrease cardiometabolic effects. This intervention is safe and can be employed as an adjuvant to the other main treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of omega-3 and vitamin D supplementation in patients with breast cancer: a systematic review

Oliveira da Silva,

Da Silva,

Weiny Barbalho Silva

et al. 2024

FNDS

View full text Add to dashboard Cite

show abstract

“…Our observations provide further evidence regarding the necessity of VD assessments and supplementation during CTH in BC patients. It seems even more important in the context of recent findings by El-Bassiouny et al showing promising clinical evidence to support the cardioprotective effects of VD against pro-inflammatory cytokines induced by doxorubicin CTH [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Kimsa-Furdzik,

Bednarek,

Hibner

et al. 2023

Metabolites

View full text Add to dashboard Cite

Background: The predictive role of vitamin D (VD) in breast cancer (BC) patients’ survival is still being investigated. This paper aims to evaluate the changes in VD metabolites during chemotherapy (CTH) and the predictive role of VD status in Caucasian BC patients treated with CTH. Methods: Vitamin D and its metabolites were assessed with reference LC–MS/MS methodology in 98 consecutive BC patients starting CHT, after 3 and 6 months, and compared to the control group. Results: The frequency of VD deficiency in BC patients was greater than in the control group (56.1% vs. 37.2%). After 6 months of CTH, the number of VD-deficient BC patients slightly increased to 60%. The concentrations of VD active forms [25(OH)D2, 25(OH)D3], and catabolites [24,25(OH)2D3 and 3-epi-25(OH)D3] decreased after 3 and 6 months of CTH compared to the baseline values. Strong positive correlations between concentrations of 3-epi-25(OH)D3 and 25(OH)D in both groups were found. Similar correlations were also observed between 24,25(OH)2D3 and 25(OH)D levels. Kaplan–Meier survival analysis showed significantly longer survival in BC patients without deficiency (>20 ng/mL) at baseline (HR = 2.44 (95% CI 1.07–5.59), p = 0.026). Conclusions: (1) Our data provide further evidence that BC patients before CTH are more VD-deficient than the general population and this deficiency increases further during CTH treatment, as observed using the reference LC-MS methodology. (2) Presented results show that VD catabolism is not affected in BC patients. (3) The poorer survival in VD-deficient BP patients supports the importance of VD supplementation in BC patients with 25(OH)D levels below 20 ng/mL.

show abstract

“…One [21] more study was included via cross-referencing. Nine studies [13,[21][22][23][24][25][26][27][28] were nally included in this systematic review and eight studies were included in the meta-analyses with a total of 592 patients. Other studies were excluded based on prede ned criteria as depicted in Supplementary Table 2.…”

Section: Search Strategy and Study Selectionmentioning

confidence: 99%

Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions: Systematic review and meta-analysis of randomized trials

et al. 2023

View full text Add to dashboard Cite

The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy

Cited by 19 publications

References 34 publications

Effects of omega-3 and vitamin D supplementation in patients with breast cancer: a systematic review

Effects of omega-3 and vitamin D supplementation in patients with breast cancer: a systematic review

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients

Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions: Systematic review and meta-analysis of randomized trials

Contact Info

Product

Resources

About